Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05486949 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine
A Phase 1 study of Healthy Subjects, sponsored by Dizal Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT05486949: Completed Phase 1 study of Healthy Subjects, sponsored by Dizal Pharmaceuticals.
NCT05486949 is a Phase 1 study of Healthy Subjects that has completed, run by Dizal Pharmaceuticals. The registered enrollment target is 32 participants, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05486949, a Phase 1 study of Healthy Subjects, has completed, sponsored by Dizal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1, single-center, nonrandomized, open-label, 2-part, fixed-sequence, drug-drug interaction (DDI) study to assess the effect of multiple doses of itraconazole, a CYP3A4 enzyme inhibitor, on the single dose PK of AZD4205 in healthy adult subjects (Part A) and to assess the effect of multiple doses of carbamazepine, a CYP3A4 inducer, on the single dose PK of AZD4205 in healthy adult subjects (Part B).
Conditions Studied
Interventions
- DRUG AZD4205 and carbamazepine
- DRUG AZD4205 and itraconazole
Study Locations (1)
Kansas
- Pharmaceutical Research Associates, Inc. - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-07-27 |
| Est. Completion | 2022-10-11 |
| Phase | Phase 1 |
What the finished NCT05486949 record still lists
NCT05486949 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 128-participant average among 69 other Healthy Subjects trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Healthy Subjects appearing as the primary indexed condition, and to 2 interventions - of which AZD4205 and carbamazepine is the first listed.
NCT05486949 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT05486949 about?
NCT05486949 is a clinical study titled "Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine". This is a Phase 1, single-center, nonrandomized, open-label, 2-part, fixed-sequence, drug-drug interaction (DDI) study to assess the effect of multiple doses of itraconazole, a CYP3A4 enzyme inhibitor, on the single dose PK of AZD4205 in healthy adult subjects (Part A) and to assess the effect of mu...
What is the current status of trial NCT05486949?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-07-27. Estimated completion is 2022-10-11.
What conditions does trial NCT05486949 study?
This clinical trial studies the following conditions: Healthy Subjects.
What interventions are being tested in trial NCT05486949?
The interventions under investigation include: AZD4205 and carbamazepine (DRUG), AZD4205 and itraconazole (DRUG).
Who is sponsoring clinical trial NCT05486949?
This trial is sponsored by Dizal Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05486949 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Subjects
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05486949's enrollment target sits among peer trials
32 35th of 69 higher than 33 of 69 other Healthy Subjects trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy Subjects trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I Study of ICP-332 in Healthy Subjects
RECRUITING · Phase 1
-
A Study to Investigate HLA-G Targeted Exosome (SOB100) in Healthy Subjects
RECRUITING · Phase 1
-
Phase 1 Study of Intravaginal KB15A
RECRUITING · Phase 1
-
A Study to Compare to the Pharmacokinetic Profile of Two Paracetamol Formulations
COMPLETED · Phase 1
-
Pharmacokinetic Study Investigating the Extent of Paracetamol Absorption From a New Formulation of Paracetamol Compared With Panadol®
COMPLETED · Phase 1
-
A Drug-Drug Interaction Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Apremilast
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI